Drug intelligence / Profile preview

tp4303

Development stage: Preclinical
Modality: Peptide-Drug Conjugates → Peptide Conjugates → Peptides
Administration: In Vitro

Overview

TP4303 is a 28-amino-acid peptide labeled with a near-infrared (NIR) fluorophore designed to bind with high affinity (kd 3.1 × 10^-8M) to VPAC receptors. These receptors are overexpressed on malignant prostate cancer cells (10^4-10^5/cell) compared to normal cells (~10/cell). When TP4303 binds to these receptors, it produces an orange fluorescence around the nucleus of malignant cells, enabling their detection under a fluorescence microscope. This property is utilized in a non-invasive diagnostic assay for prostate cancer detection using voided urine samples.

Targets

VIPR1 (Vasoactive intestinal peptide receptor 1)

Beyond the preview

Go deeper on tp4303.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tp4303.

Explore the full profile